In multivariate analysis of subsequent OS, low CD4:CD8 ratio (relative risk [RR]: 3.26, 95% CI: 1.06-10.06, p=0.039) remained a significant predictor in PG-DLBCL patients who were newly diagnosed and did not receive rituximab. The gene discussed is CD4; the disease is diffuse large B-cell lymphoma.